Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2023-03-01 00:00:00 ET · period of report 2023-02-27 · accession 0001562180-23-002037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-01 | 2023-02-27 | AKBA | Hadas Nicole R. | SVP, CLO | S - Sale | $0.81 | -6,677 | 300.6K | -2% | -$5,408 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-27 | S | D | 6,677 | $0.81 | 300,564 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. (F2) Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. |